This proposal is concerned with the molecular and anatomical investigation of two families of neurotransmitter receptors - the dopamine receptor family and the serotonin receptor family. Both belong to the so-called """"""""seven transmembrane domains"""""""" superfamily which is characterized by receptors encoded in a single protein with seven putative alpha-helical stretches which span the cell membrane and form a pore to which the ligands bind. These receptors share a number of characteristics, including the fact that they transduce their signals by coupling to G proteins, and that they exhibit extensive sequence homologies, both within and across families. Our focus on the dopamine and the serotonin receptors is due to the role of these proteins in mediating the actions of two important monoaminergic systems which have been implicated in psychiatric disorders - i.e. dopamine and its hypothesized role in schizophrenia, and serotonin and its proposed role in depression. The proposal places the larger emphasis on the dopamine receptors, their structure, regulation and expression in limbic and motor systems, and secondary emphasis on serotonin receptors and their relationship to the stress axis. We propose to study all three known members of the dopamine receptor family - D1, D2, D3, at two levels: a) a molecular/structural level in which we examine the physical characteristics of these receptor proteins in an attempt to shed some light on their physic al configuration, describe the key features of their ligand binding pocket and tease out the molecular basis for their pharmacological selectivity. b) an anatomical/regulatory level, in which we complete the neuronal mapping of the mRNA's coding for these receptors, describe their relationship to each other and to dopaminergic and dopaminoceptive neurons, study the differential expression of unique receptor subtypes in neurons with particular biochemical identities (as indicated by the neurotransmitters and neuroregulators which they express), and examine the consequences of chronic agonist and antagonist treatment on the mRNA levels. These studies will complement and extend the existing body of knowledge based on receptor binding regarding the distribution and regulation of these receptors. We shall rely on in situ hybridization, receptor autoradiography and pharmacological tools for the anatomical/regulatory studies. For the structural studies, we shall use protein expression, domain swapping, site directed mutagenesis and molecular modeling. The serotonin receptor component of this proposal is concerned primarily with the expression and regulation of the multiple cloned members of this family in brain areas of relevance to the stress axis. Of particular interest is the apparent cross-regulation between these receptors and corticosteroid receptors, as well as their potential regulation by stress- related manipulations and by antidepressant drugs with high selectivity for serotonin. These experiments will employ the same anatomical, molecular and pharmacological tools described for the dopamine receptor studies. The findings of this project will be directly relevant to our analyses of post-mortem human brains proposed under Project III.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program Projects (P01)
Project #
5P01MH042251-10
Application #
5214636
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1996
Total Cost
Indirect Cost
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hillhouse, Todd M; Porter, Joseph H (2015) A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 23:1-21
Meyers, K K; Crane, N A; O'Day, R et al. (2015) Smoking history, and not depression, is related to deficits in detection of happy and sad faces. Addict Behav 41:210-7
Lohoff, F W; Hodge, R; Narasimhan, S et al. (2014) Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing. Mol Psychiatry 19:129-39
Tomita, Hiroaki; Ziegler, Mary E; Kim, Helen B et al. (2013) G protein-linked signaling pathways in bipolar and major depressive disorders. Front Genet 4:297
Votruba, Kristen L; Langenecker, Scott A (2013) Factor structure, construct validity, and age- and education-based normative data for the Parametric Go/No-Go Test. J Clin Exp Neuropsychol 35:132-46
Turner, Cortney A; Watson, Stanley J; Akil, Huda (2012) The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 76:160-74
Vederman, Aaron C; Weisenbach, Sara L; Rapport, Lisa J et al. (2012) Modality-specific alterations in the perception of emotional stimuli in Bipolar Disorder compared to Healthy Controls and Major Depressive Disorder. Cortex 48:1027-34
Turner, Cortney A; Clinton, Sarah M; Thompson, Robert C et al. (2011) Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals. Proc Natl Acad Sci U S A 108:8021-5
Mickey, Brian J; Zhou, Zhifeng; Heitzeg, Mary M et al. (2011) Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry 68:158-66

Showing the most recent 10 out of 75 publications